Brinton Pharma to invest over Rs 3 crore to expand global RnD center in UK
The investment helps the company to engage in a thriving life sciences ecosystem, supporting their global ambitions to build next generation healthcare products.
Pune: Brinton Pharmaceutical Limited has announced that the company will invest in a global research and development center in the United Kingdom.The company plans to invest GBP 30 million over the next five years to strengthen its product pipelines, create 300 highly skilled jobs and develop innovative products for its global consumers.The proposed life sciences research and development...
Login or Register to read the full article
Pune: Brinton Pharmaceutical Limited has announced that the company will invest in a global research and development center in the United Kingdom.
The company plans to invest GBP 30 million over the next five years to strengthen its product pipelines, create 300 highly skilled jobs and develop innovative products for its global consumers.
The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company's research in the areas of biotechnology, health and life sciences. The investment helps the company to engage in a thriving life sciences ecosystem, supporting their global ambitions to build next generation healthcare products.
The company looks towards UK as a partner to achieve its international aspirations. UK provides a collaborative business environment which is dedicated to nurturing science and innovation with access to some of the finest pharmaceutical talent, excellent global connectivity and a broad range of opportunities across the healthcare and life sciences sector.
UK Prime Minister Boris Johnson said, "Trade and investment between the UK and India is creating good jobs and sustaining livelihoods in both of our countries. I'm very pleased that Brinton Pharmaceuticals has decided to join the legions of Indian companies investing in the UK, boosting our healthcare sector and driving economic growth."
Rahul Kumar Darda, Chairman and Managing Director of Brinton, said, "Our long-term business plan is based on research and innovation. The primary objective is to generate a high-quality portfolio of niche-differentiated products that answer unmet needs. This is a significant step in our long journey to growth and we are quite excited."
We continually strive for unparalleled operational excellence by harnessing on research and development, production, quality, and regulatory compliance standards. Our Global Capacity Partnership Pool (GCPP) ensures significant operational synergy in bringing innovations to life, Darda added.
Brinton has recently been in the news for its strategic alliance for Heritage Brand Krack Cream and Globally No. 1 Scholl's footcare range of products.
Brinton develops innovative formulations for consumer healthcare as well as specialty care in Dermatology, Paediatric, Respiratory & Family physician specialities as well as nutraceuticals. The organization has introduced 14 unique formulations in India. The company is planning to use its global research and development centre in the UK to create affordable novel products using niche technologies.
Read also: Brinton Pharma launches wellness, personal care range Hohner Health in India
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd